Testosterone and male contraception
- PMID: 39155802
- PMCID: PMC11556877
- DOI: 10.1097/MED.0000000000000880
Testosterone and male contraception
Abstract
Purpose of review: Rates of unintended pregnancy have remained relatively stagnant for many years, despite a broad array of female contraceptive options. Recent restrictions on access to abortion in some countries have increased the urgency for expanding contraceptive options. Increasing data suggest men are keen to utilize novel reversible male contraceptives.
Recent findings: Despite decades of clinical research in male contraception, no reversible hormonal product currently exists. Nestorone/testosterone, among other novel androgens, shows promise to finally move to pivotal Phase 3 studies and introduction to the marketplace.
Summary: Hormonal male contraception utilizes androgens or androgen-progestin combinations to exploit negative feedback that regulates the hypothalamic-pituitary-testicular axis. By suppressing release of gonadotropins, these agents markedly decrease endogenous testosterone production, lower intratesticular testosterone and suppress spermatogenesis. The addition of a progestin enhances the degree and speed of sperm suppression. The androgen component preserves a state of symptomatic eugonadism in the male. There is growing demand and acceptance of male contraceptive options in various forms. As these formulations progress through stages of drug development, regulatory oversight and communication with developers around safety and efficacy standards and garnering industry support for advancing the production of male contraceptives will be imperative.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Figures


Similar articles
-
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2023 May 15;5:CD014908. doi: 10.1002/14651858.CD014908.pub3. PMID: 36622724 Free PMC article. Updated.
-
Synthetic androgens for male contraception.Contraception. 2025 May;145:110735. doi: 10.1016/j.contraception.2024.110735. Epub 2024 Nov 6. Contraception. 2025. PMID: 39515746 Review.
-
WITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.Cochrane Database Syst Rev. 2007 Jul 18;(4):CD000150. doi: 10.1002/14651858.CD000150. Cochrane Database Syst Rev. 2007. PMID: 17636603
-
Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.Cochrane Database Syst Rev. 2000;1996(2):CD000150. doi: 10.1002/14651858.CD000150. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(4):CD000150. doi: 10.1002/14651858.CD000150. PMID: 10796496 Free PMC article. Updated.
-
Steroid hormones for contraception in men.Cochrane Database Syst Rev. 2004;(3):CD004316. doi: 10.1002/14651858.CD004316.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004316. doi: 10.1002/14651858.CD004316.pub3. PMID: 15266528 Updated.
Cited by
-
Testosterone replacement therapy and spermatogenesis in reproductive age men.Nat Rev Urol. 2025 May 9. doi: 10.1038/s41585-025-01032-8. Online ahead of print. Nat Rev Urol. 2025. PMID: 40346275 Review.
-
Male Hormonal Contraception-Current Stage of Knowledge.J Clin Med. 2025 Mar 23;14(7):2188. doi: 10.3390/jcm14072188. J Clin Med. 2025. PMID: 40217642 Free PMC article. Review.
References
-
- Bearak J, Popinchalk A, Ganatra B, et al. . Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health 2020; 8:e1152–e1161. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials